The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer

During exclusive curative radiotherapy for head and neck tumors, the patient’s organs at risk (OAR) and target volumes frequently change size and shape, leading to a risk of higher toxicity and lower control than expected on planned dosimetry. Adaptive radiotherapy is often necessary but 1) tools ar...

Full description

Bibliographic Details
Main Authors: Vincent Esteyrie, Baptiste Gleyzolle, Amélie Lusque, Pierre Graff, Anouchka Modesto, Michel Rives, Michel Lapeyre, Jacques Desrousseaux, Eliane Graulières, Gregory Hangard, François-Xavier Arnaud, Regis Ferrand, Jean-Pierre Delord, Muriel Poublanc, Muriel Mounier, Thomas Filleron, Anne Laprie
Format: Article
Language:English
Published: Elsevier 2019-05-01
Series:Clinical and Translational Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630818301265
id doaj-853faf3f1722433493b31a0134b24f2e
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Vincent Esteyrie
Baptiste Gleyzolle
Amélie Lusque
Pierre Graff
Anouchka Modesto
Michel Rives
Michel Lapeyre
Jacques Desrousseaux
Eliane Graulières
Gregory Hangard
François-Xavier Arnaud
Regis Ferrand
Jean-Pierre Delord
Muriel Poublanc
Muriel Mounier
Thomas Filleron
Anne Laprie
spellingShingle Vincent Esteyrie
Baptiste Gleyzolle
Amélie Lusque
Pierre Graff
Anouchka Modesto
Michel Rives
Michel Lapeyre
Jacques Desrousseaux
Eliane Graulières
Gregory Hangard
François-Xavier Arnaud
Regis Ferrand
Jean-Pierre Delord
Muriel Poublanc
Muriel Mounier
Thomas Filleron
Anne Laprie
The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer
Clinical and Translational Radiation Oncology
author_facet Vincent Esteyrie
Baptiste Gleyzolle
Amélie Lusque
Pierre Graff
Anouchka Modesto
Michel Rives
Michel Lapeyre
Jacques Desrousseaux
Eliane Graulières
Gregory Hangard
François-Xavier Arnaud
Regis Ferrand
Jean-Pierre Delord
Muriel Poublanc
Muriel Mounier
Thomas Filleron
Anne Laprie
author_sort Vincent Esteyrie
title The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer
title_short The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer
title_full The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer
title_fullStr The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer
title_full_unstemmed The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer
title_sort girafe phase ii trial on mvct-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer
publisher Elsevier
series Clinical and Translational Radiation Oncology
issn 2405-6308
publishDate 2019-05-01
description During exclusive curative radiotherapy for head and neck tumors, the patient’s organs at risk (OAR) and target volumes frequently change size and shape, leading to a risk of higher toxicity and lower control than expected on planned dosimetry. Adaptive radiotherapy is often necessary but 1) tools are needed to define the optimal time for replanning, and 2) the subsequent workflow is time-consuming.We designed a prospective study to evaluate 1) the validity of automatically deformed contours on the daily MVCT, in order to safely use the “dose-of the day” tool to check daily if replanning is necessary; 2) the automatically deformed contours on the replanning CT and the time gained in the replanning workflow.Forty-eight patients with T3-T4 and/or involved node >2 cm head and neck squamous cell carcinomas, planned for curative radiotherapy without surgery, will be enrolled. They will undergo treatment with helical IMRT including daily repositioning MVCTs. The contours proposed will be compared weekly on intermediate planning CTs (iCTs) on weeks 3, 4, 5 and 6. On these iCTs both manual recontouring and automated deformable registration of the initial contours will be compared with the contours automatically defined on the MVCT. The primary objective is to evaluate the Dice similarity coefficient (DSC) of the volumes of each parotid gland. The secondary objectives will evaluate, for target volumes and all OARs: the DSC, the mean distance to agreement, and the average surface-to-surface distance. Time between the automatic and the manual recontouring workflows will be compared.
url http://www.sciencedirect.com/science/article/pii/S2405630818301265
work_keys_str_mv AT vincentesteyrie thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT baptistegleyzolle thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT amelielusque thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT pierregraff thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT anouchkamodesto thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT michelrives thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT michellapeyre thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT jacquesdesrousseaux thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT elianegraulieres thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT gregoryhangard thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT francoisxavierarnaud thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT regisferrand thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT jeanpierredelord thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT murielpoublanc thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT murielmounier thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT thomasfilleron thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT annelaprie thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT vincentesteyrie girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT baptistegleyzolle girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT amelielusque girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT pierregraff girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT anouchkamodesto girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT michelrives girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT michellapeyre girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT jacquesdesrousseaux girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT elianegraulieres girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT gregoryhangard girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT francoisxavierarnaud girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT regisferrand girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT jeanpierredelord girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT murielpoublanc girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT murielmounier girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT thomasfilleron girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
AT annelaprie girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer
_version_ 1721406484098580480
spelling doaj-853faf3f1722433493b31a0134b24f2e2021-06-02T08:25:47ZengElsevierClinical and Translational Radiation Oncology2405-63082019-05-01163439The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancerVincent Esteyrie0Baptiste Gleyzolle1Amélie Lusque2Pierre Graff3Anouchka Modesto4Michel Rives5Michel Lapeyre6Jacques Desrousseaux7Eliane Graulières8Gregory Hangard9François-Xavier Arnaud10Regis Ferrand11Jean-Pierre Delord12Muriel Poublanc13Muriel Mounier14Thomas Filleron15Anne Laprie16Radiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, FranceRadiation Oncology, Centre Jean Perrin, Clermont-Ferrand, FranceBiostatistics Unit, Institut Claudius Regaud-, Institut Universitaire du Cancer de Toulouse – Oncopole Toulouse, FranceRadiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, FranceRadiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, FranceRadiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, FranceRadiation Oncology, Centre Jean Perrin, Clermont-Ferrand, FranceRadiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, FranceEngineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceEngineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceEngineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceEngineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceClinical Trials Office , Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceClinical Trials Office , Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceClinical Trials Office , Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceBiostatistics Unit, Institut Claudius Regaud-, Institut Universitaire du Cancer de Toulouse – Oncopole Toulouse, FranceRadiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France; Corresponding author.During exclusive curative radiotherapy for head and neck tumors, the patient’s organs at risk (OAR) and target volumes frequently change size and shape, leading to a risk of higher toxicity and lower control than expected on planned dosimetry. Adaptive radiotherapy is often necessary but 1) tools are needed to define the optimal time for replanning, and 2) the subsequent workflow is time-consuming.We designed a prospective study to evaluate 1) the validity of automatically deformed contours on the daily MVCT, in order to safely use the “dose-of the day” tool to check daily if replanning is necessary; 2) the automatically deformed contours on the replanning CT and the time gained in the replanning workflow.Forty-eight patients with T3-T4 and/or involved node >2 cm head and neck squamous cell carcinomas, planned for curative radiotherapy without surgery, will be enrolled. They will undergo treatment with helical IMRT including daily repositioning MVCTs. The contours proposed will be compared weekly on intermediate planning CTs (iCTs) on weeks 3, 4, 5 and 6. On these iCTs both manual recontouring and automated deformable registration of the initial contours will be compared with the contours automatically defined on the MVCT. The primary objective is to evaluate the Dice similarity coefficient (DSC) of the volumes of each parotid gland. The secondary objectives will evaluate, for target volumes and all OARs: the DSC, the mean distance to agreement, and the average surface-to-surface distance. Time between the automatic and the manual recontouring workflows will be compared.http://www.sciencedirect.com/science/article/pii/S2405630818301265